<DOC>
	<DOCNO>NCT00006008</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient relapsed refractory acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Relapsed Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete remission rate patient relapse refractory acute lymphoblastic leukemia treat arsenic trioxide . - Determine toxic effect induction arsenic trioxide patient population . OUTLINE : Patients stratify accord administration schedule arsenic trioxide ( 5 day week vs 7 day week ) . Patients receive arsenic trioxide IV 1 hour daily bone marrow blast less 5 % maximum 60 day . Beginning 3-6 week induction , patient achieve complete remission receive arsenic trioxide IV 1 hour daily either 5 day 7 day week 25 day . Subsequent consolidation course give 4 week treatment-free interval course . Treatment continue maximum 5 consolidation course absence unacceptable toxicity disease progression . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 13-40 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Morphologically proven acute lymphoblastic leukemia ( ALL ) Subtypes L1 , L2 , L3 Bone marrow morphology great 25 % lymphoblasts ALL morphology cytochemistry myeloid marker eligible Refractory induction therapy relapse follow chemotherapy autologous blood bone marrow transplantation Any number prior relapse allow No relapse follow allogeneic transplantation Prior CNS leukemia allow treat currently diseasefree PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 6 month Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL SGOT/SGPT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Renal : Creatinine great 2 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant active infection No medical condition would likely decrease life expectancy No prior malignancy within past 5 year except cure basal squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : At least 2 week since prior systemic corticosteroid Radiotherapy : Not specify Surgery : Not specify Other : No concurrent antibiotic active resolve infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>L1 adult acute lymphoblastic leukemia</keyword>
	<keyword>L2 adult acute lymphoblastic leukemia</keyword>
	<keyword>L3 adult acute lymphoblastic leukemia</keyword>
</DOC>